Claret Asset Management’s Redhill Biopharma RDHL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-228
| Closed | -$32K | – | 158 |
|
|
2022
Q4 | $32K | Buy |
228
+133
| +140% | +$18.7K | 0.01% | 148 |
|
|
2022
Q3 | $48K | Hold |
95
| – | – | 0.01% | 149 |
|
|
2022
Q2 | $83K | Hold |
95
| – | – | 0.02% | 149 |
|
|
2022
Q1 | $240K | Hold |
95
| – | – | 0.05% | 136 |
|
|
2021
Q4 | $246K | Buy |
95
+32
| +51% | +$82.9K | 0.05% | 134 |
|
|
2021
Q3 | $287K | Buy |
63
+8
| +15% | +$36.4K | 0.05% | 133 |
|
|
2021
Q2 | $378K | Hold |
55
| – | – | 0.06% | 128 |
|
|
2021
Q1 | $402K | Hold |
55
| – | – | 0.07% | 121 |
|
|
2020
Q4 | $444K | Buy |
55
+10
| +22% | +$80.7K | 0.09% | 115 |
|
|
2020
Q3 | $460K | Hold |
45
| – | – | 0.1% | 106 |
|
|
2020
Q2 | $301K | Sell |
45
-25
| -36% | -$167K | 0.07% | 133 |
|
|
2020
Q1 | $317K | Sell |
70
-5
| -7% | -$22.6K | 0.09% | 115 |
|
|
2019
Q4 | $456K | Hold |
75
| – | – | 0.09% | 119 |
|
|
2019
Q3 | $529K | Buy |
75
+13
| +21% | +$91.7K | 0.11% | 99 |
|
|
2019
Q2 | $400K | Sell |
62
-6
| -9% | -$38.7K | 0.08% | 122 |
|
|
2019
Q1 | $561K | Hold |
68
| – | – | 0.11% | 98 |
|
|
2018
Q4 | $375K | Buy |
68
+20
| +42% | +$110K | 0.08% | 115 |
|
|
2018
Q3 | $420K | Hold |
48
| – | – | 0.08% | 122 |
|
|
2018
Q2 | $405K | Hold |
48
| – | – | 0.08% | 116 |
|
|
2018
Q1 | $246K | Buy |
48
+5
| +12% | +$25.6K | 0.06% | 138 |
|
|
2017
Q4 | $219K | Buy |
+43
| New | +$219K | 0.05% | 145 |
|